Goldenrod Is Developing Next Generation Phosphodiesterase 4 Inhibitors
Selective, brain penetrant phosphodiesterase inhibitors for a variety of neurological indications
About Us
Goldenrod Therapeutics is a portfolio company of Fannin based in Houston, Texas. We are committed to developing a next generation phosphodiesterase 4 inhibitor that offer a much-needed therapeutic alternative to important health problems like substance use disorders (SUDs), neurodegenerative diseases, and pain. While previous generations had numerous side effects, this second generation aims to avoid such issues while having significant brain penetration, allowing for novel indications.
These have the potential to establish new standards of care and help tens of millions around the world.
Innovation
We are developing first-in-class small molecule drugs that are next generations selective inhibitors of PDE4B enzymes.
Orally bioavailable, brain-penetrant molecules
Designed to inhibit this target while avoiding adverse events, like nausea, currently associated with available inhibitors
Our lead clinical candidate is a highly specific inhibitor of the phosphodiesterase commonly found in the brain (PDE4B)
Inhibition of this pathway increases cAMP, producing an anti-inflammatory effect in microglia and having neurorestorative properties
News and Publications
